News

Real-Time Identity Analytics and Federated Trust Combine Security, Low Total Cost of Ownership and Optimal User Experience San Jose, Calif. – February 20, 2014 – ThreatMetrix™, the fastest-growing provider of context-based security and advanced fraud prevention solutions, today announced a revolutionary offering that improves the security associated with traditional username and password protection for accessing enterprise applications in conjunction with the upcoming RSA Conference 2014, February 24-28 at Moscone Center, San Francisco. With the advent of bring-your-own-device (BYOD) and cloud-based applications, today’s enterprise security professionals are challenged with augmenting the application access security that can be obtained through simple username and password verification and cumbersome two-factor authentication with minimal impact to the […]

ThreatMetrix Leads the Industry in “Building Trust on the Internet” to Reduce Fraud and Facilitate Fast and Frictionless Online Transactions San Jose, CA – January 29, 2014 – ThreatMetrix™, the fastest growing provider of context-based authentication and advanced Web fraud prevention solutions, today announced a compilation of record 2013 milestones and its emergence as one of the largest fully anonymized global identity and fraud networks in the world. In 2013, the rules governing global cybercrime protection changed. Global governments now assign more importance to individual consumer privacy than to the rapidly increasing financial losses online retailers, enterprises and financial institutions face at the hands of highly sophisticated global cybercriminals. “We work

Minnesota, United States and Melbourne, Australia – January 7, 2014 – Osprey Medical Inc. (ASX: OSP) today announced enrollment of the first patient in the AVERT IDE Clinical Study. The patient was enrolled at Harbor UCLA Medical Center in Torrance, California by Dr William French. This trial will evaluate the Company’s AVERT™ System for a marketing claim expansion to include “reduction of Contrast Induced Nephropathy (CIN)” for patients undergoing angiogram or stenting procedures. The randomized, multi-center, IDE trial will be enrolling approximately 700 patients at up to 45 sites in the U.S., Canada, Europe, Australia, and New Zealand. In addition to evaluating the effectiveness of the AVERT System for CIN

Minnesota, United States and Melbourne, Australia – January 2, 2014 – Osprey Medical Inc. (ASX: OSP) today announced publication of results from the pilot clinical trial of the AVERT system (Contrast Conservation System/CCS). The study which was conducted in late 2012 at the Alfred Hospital in Melbourne Australia by Dr David Kaye and Dr Stephen Duffy, was titled “Reducing iodinated contrast volume by manipulating injection pressure during coronary angiography” and was published ahead of press on-line in the December 2013 edition of leading industry peer-reviewed journal “Catheterization and Cardiovascular Interventions”. The 21-patient pilot clinical trial, demonstrated that the use of the AVERT System was associated with a highly significant 40%

Minnesota, United States and Melbourne, Australia – January 2, 2014 – Osprey Medical Inc. (ASX: OSP) today announced publication of results from the pilot clinical trial of the AVERT system (Contrast Conservation System/CCS). The study which was conducted in late 2012 at the Alfred Hospital in Melbourne Australia by Dr David Kaye and Dr Stephen Duffy, was titled “Reducing iodinated contrast volume by manipulating injection pressure during coronary angiography” and was published ahead of press on-line in the December 2013 edition of leading industry peer-reviewed journal “Catheterization and Cardiovascular Interventions”. The 21-patient pilot clinical trial, demonstrated that the use of the AVERT System was associated with a highly significant 40%

Greensboro, NC November 18, 2013 – In June the US Food and Drug Administration’s Center for Veterinary Medicine approved the first application of Piedmont Pharmaceuticals’ invention of a soft chew formulation containing a veterinary medicine. This flavored soft chew formulation contains carprofen and is labeled for the relief of pain and inflammation from osteoarthritis and the control of post-operative pain in dogs. It is the first and only flavored, soft and chewable medicine in the pain category. Beyond the Animal Health sector this soft chew formulation is patented for use in delivering human pharmaceutical medications orally. Piedmont has demonstrated positive data supporting the use of two common OTC medications in

Minnesota, United States and Melbourne, Australia – November 18, 2013 – Osprey Medical Inc. (ASX: OSP) today announced that Dr. Roxana Mehran will be the Principal Investigator (PI) of the AVERT Trial. This trial will evaluate the Company’s AVERT™ System for a marketing claim expansion to include “reduction of Contrast Induced Nephropathy (CIN)” for patients undergoing angiogram or stenting procedures. The randomized, multi-center, IDE trial will be enrolling approximately 700 patients at up to 45 sites in the U.S., Canada, Europe, Australia, and New Zealand. Dr Mehran is a U.S. interventional cardiologist with world-recognized expertise in the area of CIN. She is Professor of Medicine and Director of Interventional Cardiovascular

EDEN PRAIRIE, Minn., Oct. 29, 2013 (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (Nasdaq:SSH) announced today that the initial C-Pulse® System patient data of its ongoing OPTIONS HF EU trial, will be presented by Professor Thomas Krabatsch, Director of Mechanical Circulatory Support at the German Heart Institute, Berlin to the investment community at Sunshine Heart’s third annual analyst breakfast event, held this morning at 7:30 a.m. PDT at the W Hotel San Francisco. As announced on October 22, 2013, the event also includes presentations from Dr. Andrew Kao, Associate Professor of Medicine at the University of Missouri-Kansas City; as well as Dr. William Cohn, Director of Minimally Invasive Surgical Technology of

Minnesota, United States and Melbourne, Australia – October 22, 2013 – Osprey Medical Inc. (ASX: OSP) today announced the first patient enrolment in its Limb Recovery™ System efficacy study. This technology allows clinicians to use existing antibiotic therapy in a more targeted and aggressive way in patients with diabetes who present with life or limb threatening foot infections. The patient was enroled at the Royal Melbourne Hospital in Melbourne, Australia. Osprey’s efficacy study will involve a 20 patient randomized clinical trial comparing the effectiveness of Osprey’s percutaneous perfusion Limb Recovery System with standard intravenous delivery of antibiotic therapy for treatment of severe limb infections. The system enables the circulation of

Brings enterprise-grade endpoint data protection to public sync and share services SEATTLE, October 1st, 2013 – Datacastle®, a market leader for protecting enterprises from endpoint data loss and data breaches, today announced that its flagship product, Datacastle RED™  now supports secure backup and restore of company data when using major cloud sync and share services such as DropBox, Microsoft SkyDrive, Box, Google Drive, and Amazon Cloud Drive. This new capability is added to Datacastle’s recognized QuickCache™ and RoamSmart™ technologies that support intelligent backup and recovery roaming across hybrid cloud deployments with mobile broadband detection functionality. “While many vendors in the enterprise IT sector are trying to provide companies with a “rip and replace” alternative to these

EDEN PRAIRIE, Minn., Sept. 24, 2013 (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (Nasdaq:SSH) announced today the closing of its previously announced underwritten public offering of 4,381,500 shares of its common stock, which includes the full overallotment of 571,500 shares, at a price to the public of $10.50 per share. The net proceeds from the sale of shares by Sunshine Heart, after underwriting discounts and other offering expenses, total approximately $42.6 million. Piper Jaffray & Co. and Cowen and Company, LLC acted as joint book-running managers and Lazard Capital Markets LLC acted as co-lead manager for the offering. Craig-Hallum Capital Group and Northland Securities, Inc. acted as co-managers for the offering.

September 23rd 2013, Reading, Berkshire: Mesaplexx announces that the company and its xCube technology have been shortlisted for two prestigious industry awards in the past fortnight. Mesaplexx has been shortlisted as a potential ‘Innovator of the Year’ in the Growing Business Awards, the most widely supported national awards program, recognising successful UK SMEs and entrepreneurs. Backed by Lloyds Bank, The CBI and RealBusiness Magazine, the awards have celebrated successful British businesses for the past 15 years. Mesaplexx’s xCube technology has also been nominated to receive a Global Business Excellence Award for Outstanding Innovation, an awards program that recognises and rewards business excellence in all sectors. The patented xCube range of filters

EDEN PRAIRIE, Minn., Sept. 12, 2013 (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (Nasdaq:SSH) announced today the first patient implant in the Company’s U.S. pivotal trial, COUNTER HF. The COUNTER HF study is a prospective, randomized, multicenter, controlled trial that will evaluate the safety and efficacy of the C-Pulse system for the treatment of NYHA Class III and ambulatory Class IV heart failure. Integral to the COUNTER HF study is the assessment of C-Pulse’s unique balloon counterpulsation treatment designed to improve heart function and reduce re-hospitalizations due to worsening heart failure. “We are excited to be part of this innovative clinical trial,” said cardiothoracic surgeon, Sanjeev Aggarwal, M.D., Director of Mechanical

Eden Prairie, MN: August 27, 2013: Sunshine Heart, Inc. (NASDAQ: SSH) announced that, effective today, Patrick Verta, MD, has joined the Company as Chief Medical Officer. Dr. Verta brings over 20 years of experience in the medical field with the majority of time spent in the cardiovascular field. Prior to joining Sunshine Heart, Dr. Verta served as Chief Medical Officer and Vice President of Clinical Affairs at Neomend, a medical device company that developed and commercialized the only FDA-approved sealant for air leaks following lung surgery via open thoracotomy. The company was acquired by Bard/Davol in October 2012. Before Neomend, he served as Medical Director of Clinical Research and Business

Datacastle brings enterprise-grade endpoint data protection to the IBM SmartCloud SEATTLE, June 25th, 2013 – Datacastle®, a market leader for protecting enterprises from endpoint data loss and data breaches, today announced that its flagship product, Datacastle RED is now certified for the IBM SmartCloud and available worldwide through the IBM Partner Network. Through the partnership both IBM and Datacastle customers will be able to adopt a robust cloud architecture and service model without having to make traditional investments in enterprise IT to support endpoint backup and security. Customers will benefit from IBM’s geographic footprint and security investments as well as the company’s experience as a global service provider. “Endpoint backup and recovery have become increasingly important

Greensboro, NC. Last week the US Food and Drug Administration’s Center for Veterinary Medicine approved the first application of Piedmont Pharmaceuticals’ invention of a canine soft chew formulation containing a veterinary medicine. This flavored soft chew formulation contains carprofen and is labelled for the relief of pain and inflammation from osteoarthritis and the control of post-operative pain in dogs. It is the first and only flavored, soft and chewable medicine in the pain category. The soft chew formulation will provide pet owners with a convenient and friendly way to medicate dogs. According to Roland Johnson, Chairman and CEO of Piedmont Pharmaceuticals, “The veterinary pharmaceutical industry has been working on a

June 4th 2013, Small Cells World Summit, London: Mesaplexx announces that xCube 1800 MHz filter reference designs for active antennas, small cells and compact radio systems are now in commercial deployment. The xCube range of filters and duplexers from Mesaplexx offer mobile network vendors high power handling, low insertion loss and high isolation in a light, compact, cool-running format. Mesaplexx’s patented xCube filter technology uses multimode resonators with optimized performance-enhancing coupling techniques, to deliver performance characteristics associated with far bigger and heavier duplexers. This makes them ideal for carrier-grade small cell deployments and active antennas, which demand high performance in a small, compact and lightweight package. The xCube 1800 MHz duplexer

Datacastle introduces groundbreaking RoamSmart™ technology for protecting mobile workforce data worldwide. SEATTLE, March 27, 2013 – Datacastle®, a market leader for protecting enterprises from endpoint data loss and data breaches, today announced the release of the latest version of its flagship product, Datacastle RED. Datacastle RED v6 introduces RoamSmart™ technology for providing network-optimized data protection for increasingly distributed and mobile workforces. Datacastle’s RoamSmart™ technology enables IT managers to provide a friction-free end user experience while meeting organizational security and compliance requirements worldwide. Datacastle’s RoamSmart™ technology includes: LTE, 4G, and 3G mobile broadband detection and backup policy enforcement Intelligent roaming between cloud-based vaults and QuickCaches located on corporate LAN’s or remote offices accelerating time

  AdGent Digital CEO, Cam Yuill, offers his thoughts to Skip Brand (CEO, Martini Media) on the advertising and branding opportunities made possible by the rapid increase of content consumption on tablet devices. http://www.mediapost.com/publications/article/195367/real-time-branding-rich-media-and-the-tablet.html?edition=57643#axzz2NHbHdjBz And Cam writes further on the effects of new streaming channels and the effectiveness and measurement of advertising through those channels. http://pandodaily.com/2013/03/12/nielsens-evolution-and-the-coming-of-the-ad-buy-structure-shake-up/

The ThreatMetrix Cybercrime Defender Platform was Honored in the Most Innovative Security Product (Software) of the Year Category San Jose, CA – March 5, 2013 – ThreatMetrix™, the fastest-growing provider of integrated cybercrime prevention solutions, today announced that Info Security Products Guide, the industry’s leading information security research and advisory guide, has named the ThreatMetrix Cybercrime Defender Platform a Bronze winner of the 2013 Global Excellence Awards in Most Innovative Security Product (Software) of the Year category. The security industry celebrated its 9th Annual 2013 Global Excellence Awards in San Francisco by honoring excellence in every facet of the industry including products, people behind the successes and best companies. ThreatMetrix’s

Mobile World Congress is, for many in the mobile community, a pivotal point in the business calendar.  There are always a number of dominant themes at the show and this year Small Cells, in all their various guises, stepped up into the mainstream. Mesaplexx, a pioneer and innovator in radio filter technology, has created a great summary of the Small Cell landscape and the technology implications that help mobile operators avoid the ever-present capacity crunch.  If you’re interested in understanding this landscape, take a look at the white paper on Mesaplexx web site titled “Active Antennas and Small Cells – Why Filters Matter”.  Highly recommended.

Datacastle Corporation Vice President, Phil Evans, shares his thoughts on the challenges of selecting a cloud provider, and most importantly on the key consideration of security policy. http://www.techbubbles.co.uk/blog/the-buck-stops-with-you-advice-when-selecting-a-cloud-provider/#more-2994

  AdGent Digital CEO offers his thoughts on live streaming of the Super Bowl to tablet devices…. http://venturebeat.com/2013/02/04/cbs-super-bowl-stream/ ….and joins a panel of ad industry experts to critique the 2013 class of Super Bowl ads http://www.hlntv.com/article/2013/02/04/super-bowl-commercials-best-worst-panel-reviews

Brisbane, QLD, Australia, 25th January 2013 – Mesaplexx is pleased to announce that the Australian office, previously sited at Eight Mile Plains, has moved to a new location in Brisbane’s West End district. The office, home to much of Mesaplexx’s intense research and development has moved to enable the set up of a new, dedicated R&D zone, to keep pace with the company’s rapid innovations and aggressive development plans. Brisbane’s West End district, in the city suburbs, is one of the city’s oldest districts, close to both the University of Queensland and Griffith University, which, along with a strong café culture, brings a diverse and exciting buzz to the area. In

The following thoughts from an article by Mark Bole CEO of Talu Investee, Mesaplexx Pty Ltd.  The time is right for disruptive radio filter technology….. Delivering LTE Coverage and Capacity Gains – Why Radio Filters Matter Unprecedented growth in mobile data traffic continues to increase expectations on LTE technology. The pressure is on the operator and supporting vendor community to maximise spectrum efficiency to recoup substantial financial investment and sustain profitability. However, few industry experts expect LTE to carry the data burden in isolation; with many pointing to a collaboration of supporting technologies and techniques, to drive spectral efficiency and maximise network coverage and capacity to meet rising demand. Active

San Jose based internet threat company, Threatmetrix, has been recognised for its continued stellar presence in the online secutiry domain. http://www.businessinsider.com/15-most-important-security-startups-2013-1?op=1  

AdGent Digital CEO, Cam Yuill, delves into the world of publishers, content subscriptions, and HTML5. http://www.huffingtonpost.com/cameron-yuill/why-publishers-should-hat_b_2457882.html

Datacastle Corporation Vice President, Craig Blessing, talks with Microsoft TechNet Radio about the use of Microsoft Azure to Protent Business Data. http://channel9.msdn.com/Shows/TechNet+Radio/TechNet-Radio-Cloud-Innovators–How-Datacastle-uses-Windows-Azure-to-Protect-Business-Data  

 Acquisition of TrustDefender, Successful Funding Round and Key Additions to the Management Team Contributed to ThreatMetrix’s Exponential Growth San Jose, CA – January 8, 2013 – ThreatMetrix™, the fastest-growing provider of integrated cybercrime prevention solutions, today announced its exponential growth in 2012 highlighted by the acquisition of TrustDefender, record revenue, billings and transaction volume, and the addition of hundreds of new customers. “The acquisition and successful integration of TrustDefender kicked off our most impressive year of growth to date,” said Reed Taussig, president and CEO, ThreatMetrix. “We’ve now delivered 16 consecutive quarters of growth in customer billings. We look forward to another exceptional year protecting our customers from fraud, malware

Bayer HealthCare Introduces ResultixTM, a New Tick Killing Solution for Dogs and Cats Pet owners and veterinarians can kill ticks without the ick! Shawnee, Kans, November 29, 2012 – Today, Bayer HealthCare LLC Animal Health Division made it easy to kill ticks on dogs and cats with Resultix, a new, simple spray-on formula that kills attached or crawling ticks. Bayer HealthCare debuted Resultix at the opening of BarkWorld Expo, a pet social media conference in Atlanta, Ga on October 26. Resultix provides an effective way to kill ticks and can be used as often as needed. Just two sprays of Resultix will dissolve the outer wax layer that covers the